Avalon Trust Co Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, HoldingsChannel.com reports. The firm bought 50 shares of the biopharmaceutical company’s stock, valued at approximately $36,000.

A number of other hedge funds have also made changes to their positions in REGN. GSA Capital Partners LLP bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at $665,000. Huntington National Bank lifted its position in shares of Regeneron Pharmaceuticals by 5.8% during the third quarter. Huntington National Bank now owns 605 shares of the biopharmaceutical company’s stock worth $636,000 after purchasing an additional 33 shares during the last quarter. Signature Estate & Investment Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter worth about $313,000. Empowered Funds LLC increased its holdings in Regeneron Pharmaceuticals by 7.1% in the third quarter. Empowered Funds LLC now owns 1,652 shares of the biopharmaceutical company’s stock valued at $1,737,000 after buying an additional 109 shares during the last quarter. Finally, Schear Investment Advisers LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $397,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.0 %

Regeneron Pharmaceuticals stock opened at $666.87 on Monday. The company’s 50-day moving average price is $694.91 and its two-hundred day moving average price is $831.18. The stock has a market cap of $72.91 billion, a price-to-earnings ratio of 17.42, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $11.86 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on REGN shares. Bernstein Bank decreased their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. Bank of America reaffirmed an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Finally, Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.